VASORELAXANT ACTIONS OF 5-OH-INDAPAMIDE, A MAJOR METABOLITE OF INDAPAMIDE - COMPARISON WITH INDAPAMIDE, HYDROCHLOROTHIAZIDE AND CICLETANINE

被引:11
作者
CALDER, JA
SCHACHTER, M
SEVER, PS
机构
[1] Department of Clinical Pharmacology, St. Mary's Hospital Medical School, Imperial College of Science, Technology and Medicine, London
关键词
INDAPAMIDE; 5-OH-INDAPAMIDE; HYDROCHLOROTHIAZIDE; CICLETANINE; K+; CA2+;
D O I
10.1016/0014-2999(94)90244-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
5-OH-Indapamide is a principal metabolite of indapamide, and possesses similar antihypertensive and diuretic properties. This study investigated the mechanisms of the acute vasodilator actions of 5-OH-indapamide, indapamide, hydrochlorothiazide and cicletanine and their interaction with ion channels in isolated guinea pig mesenteric arteries. Hydrochlorothiazide, cicletanine and 5-OH-indapamide relaxed noradrenaline-constricted vessels significantly more than K+-constricted vessels (P < 0.001) and the relaxations were reduced in the presence of charybdotoxin (P < 0.001). 5-OH-Indapamide-induced relaxation was reduced (by 42% at 30 mu M) by glibenclamide (P < 0.001). Hydrochlorothiazide, cicletanine and 5-OH-indapamide (all at 10 mu M) were weak Ca2+ antagonists shifting the Ca2+ dose-response curves half a log unit to the right (P < 0.01). Indapamide was a more potent inhibitor, a 10 mu M concentration shifting the Ca2+ dose-response curve three log units to the right and reducing maximal-induced Ca2+ contraction by 72% (P < 0.001). Hydrochlorothiazide, cicletanine and 5-OH-indapamide-induced relaxations appear to be partly mediated via Ca2+-activated K+ channels; 5-OH-Indapamide-induced relaxation is also partly mediated via ATP-sensitive K+ channels. Indapamide is a potent Ca2+ antagonist.
引用
收藏
页码:185 / 191
页数:7
相关论文
共 34 条
[1]   COMPARATIVE BIOAVAILABILITY AND PHARMACOKINETICS OF HYDROCHLOROTHIAZIDE FROM ORAL TABLET DOSAGE FORMS, DETERMINED BY PLASMA-LEVEL AND URINARY-EXCRETION METHODS [J].
BARBHAIYA, RH ;
PATEL, RB ;
CORRICKWEST, HP ;
JOSLIN, RS ;
WELLING, PG .
BIOPHARMACEUTICS & DRUG DISPOSITION, 1982, 3 (04) :329-336
[2]  
BRAYDEN JE, 1991, BLOOD VESSELS, V28, P147
[3]  
CALDER J A, 1991, Journal of Hypertension, V9, pS427
[4]  
CALDER J A, 1992, British Journal of Pharmacology, V105, p307P
[5]   INTERACTION BETWEEN CICLETANINE AND THE EICOSANOID SYSTEM IN HUMAN SUBCUTANEOUS RESISTANCE ARTERIES [J].
CALDER, JA ;
SCHACHTER, M ;
SEVER, PS .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1992, 44 (07) :574-578
[6]  
CAMPBELL DB, 1990, AM J CARDIOL, V65, pH11
[7]  
CHABRIER PE, 1988, CARDIOVASC DRUG REV, V6, P66
[8]  
DEUTSCH C, 1991, J BIOL CHEM, V266, P3668
[9]   INVITRO VASCULAR EFFECTS OF CICLETANINE IN PREGNANCY-INDUCED HYPERTENSION [J].
EBEIGBE, AB ;
CABANIE, M .
BRITISH JOURNAL OF PHARMACOLOGY, 1991, 103 (04) :1992-1996
[10]  
EDWARDS G, 1990, PHARM MANUFACTURING, P29